Pfizer Inc. (NYSE:PFE) Stock Holdings Reduced by AlphaCentric Advisors LLC

AlphaCentric Advisors LLC lessened its position in shares of Pfizer Inc. (NYSE:PFE) by 20.0% during the second quarter, Holdings Channel reports. The institutional investor owned 140,000 shares of the biopharmaceutical company’s stock after selling 35,000 shares during the quarter. Pfizer accounts for 2.9% of AlphaCentric Advisors LLC’s holdings, making the stock its 4th largest holding. AlphaCentric Advisors LLC’s holdings in Pfizer were worth $3,917,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the company. Olistico Wealth LLC purchased a new position in shares of Pfizer in the second quarter valued at $25,000. MFA Wealth Advisors LLC purchased a new stake in shares of Pfizer in the second quarter worth about $29,000. Creekmur Asset Management LLC purchased a new position in Pfizer during the fourth quarter valued at approximately $32,000. Trivant Custom Portfolio Group LLC lifted its stake in Pfizer by 100.0% in the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 600 shares in the last quarter. Finally, DiNuzzo Private Wealth Inc. bought a new position in Pfizer in the 4th quarter valued at $37,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

PFE has been the topic of a number of recent analyst reports. UBS Group increased their price objective on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. Morgan Stanley boosted their price objective on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a report on Thursday, May 2nd. Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and raised their target price for the company from $28.00 to $34.00 in a research note on Wednesday, August 7th. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Monday, August 19th. Finally, Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Eight investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $34.54.

Pfizer Trading Up 0.1 %

NYSE:PFE traded up $0.02 during mid-day trading on Monday, reaching $28.92. 16,403,924 shares of the company’s stock traded hands, compared to its average volume of 38,871,281. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $36.94. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. The company has a 50 day moving average price of $28.85 and a 200-day moving average price of $27.97. The firm has a market capitalization of $163.88 billion, a price-to-earnings ratio of -482.17, a PEG ratio of 0.98 and a beta of 0.69.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The company had revenue of $13.28 billion during the quarter, compared to analyst estimates of $12.96 billion. During the same quarter last year, the firm posted $0.67 earnings per share. The firm’s revenue was up 2.1% on a year-over-year basis. On average, sell-side analysts predict that Pfizer Inc. will post 2.68 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be given a dividend of $0.42 per share. The ex-dividend date is Friday, July 26th. This represents a $1.68 annualized dividend and a yield of 5.81%. Pfizer’s payout ratio is -2,800.00%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.